419 related articles for article (PubMed ID: 22897628)
1. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
2. Role of C-reactive protein as a biomarker for renal cell carcinoma.
Saito K; Kihara K
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1979-89. PubMed ID: 21110763
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein in urologic cancers.
Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein as a biomarker for urological cancers.
Saito K; Kihara K
Nat Rev Urol; 2011 Oct; 8(12):659-66. PubMed ID: 22025173
[TBL] [Abstract][Full Text] [Related]
5. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
Bedke J; Chun FK; Merseburger A; Scharpf M; Kasprzyk K; Schilling D; Sievert KD; Stenzl A; Kruck S
BJU Int; 2012 Dec; 110(11 Pt B):E771-7. PubMed ID: 23134582
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune disease and subsequent urological cancer.
Liu X; Ji J; Forsti A; Sundquist K; Sundquist J; Hemminki K
J Urol; 2013 Jun; 189(6):2262-8. PubMed ID: 23228387
[TBL] [Abstract][Full Text] [Related]
9. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
10. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
11. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA
J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861
[TBL] [Abstract][Full Text] [Related]
12. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
[TBL] [Abstract][Full Text] [Related]
13. [Multiple urologic tumors in autopsy material].
Tiszlavicz L; Szalay I
Orv Hetil; 1993 Mar; 134(11):577-81. PubMed ID: 8446411
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
15. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
[TBL] [Abstract][Full Text] [Related]
16. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
18. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol.
Meye A; Bilkenroth U; Schmidt U; Füssel S; Robel K; Melchior AM; Blümke K; Pinkert D; Bartel F; Linne C; Taubert H; Wirth MP
Int J Oncol; 2002 Sep; 21(3):521-30. PubMed ID: 12168095
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
[TBL] [Abstract][Full Text] [Related]
20. Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries.
Fischer CG; Waechter W; Kraus S; Fuentecilla Perez E; Weidner W; Dudeck J
Cancer; 1998 Feb; 82(4):775-83. PubMed ID: 9477112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
